Discover how tirzepatide, a next‑generation peptide drug and dual GIP/GLP‑1 receptor agonist, is transforming obesity treatment, improving glycemic control, and reducing cardiometabolic risk through advanced peptide engineering and multi‑receptor targeting.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs